drugset / Trial / NCT05098522

Allergen Challenge Trial of IRL201104 in Seasonal Allergic Rhinitis

NCT05098522 ↗

Phase 2 Completed 63 enrolled Revolo Biotherapeutics
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this allergen challenge study is to assess the efficacy of IRL201104 compared with placebo in adult participants with seasonal allergic rhinitis.

Timeline

Start
2021-11-04
Primary completion
2023-03-27
Completion
2023-03-27

Drugs

EvaluationDrugModalityDoseRoute
Subject IRL201104 Protein / enzyme biologic — Intravenous